InGel Therapeutics is developing neuro-protective regenerative cell therapies to treat retinal degradation. Retinal degeneration involves progressive failures in multiple systems necessitating a more sophisticated approach to target multiple pathways at once. Using their cellular development platform and hydrogel delivery platform, InGel engineering a biomimetic hydrogel matrix to embed the in vivo delivery of retinal neurons. InGel’s technology can be offered as a therapeutic through either intravitreal or subretinal injection and is being tested to treat complex retinal degenerative diseases.

InGel Therapeutics

Founded: 2022
Location: Allston, MA
Employee range: 1 - 10
Clinical stage: RD
Therapy area: ophthalmology
Drug types: OPH
Lead product: Undisclosed

Drug notes:

About:

Jobs: